Published in J Immunother Cancer on August 19, 2014
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines (Basel) (2016) 0.77
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol (2017) 0.75
The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. Oncoimmunology (2015) 0.75
Artificial human antigen presenting cells are superior to dendritic cells at inducing cytotoxic T cell responses. Immunology (2017) 0.75
Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8(+) T cells. Clin Transl Immunology (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Renal-cell carcinoma. N Engl J Med (1996) 11.46
Renal-cell carcinoma. N Engl J Med (2005) 10.17
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother (2009) 2.86
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm (2008) 1.21
Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol (2013) 1.08
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int J Urol (2012) 1.03
Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol (2010) 1.01
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother (2003) 0.99
Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J Leukoc Biol (2007) 0.90
Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol (2009) 0.88
The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Methods (2004) 0.86
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist (2009) 0.84
Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol (2007) 0.83
Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int J Urol (2002) 0.79
Efficient responses in a murine renal tumor model by electroloading dendritic cells with whole-tumor lysate. J Immunother (2005) 0.78
Laparoscopic repair of a ureteric sciatic hernia: report of a case. Case Rep Urol (2014) 0.75